Advertisement

Journal of General Internal Medicine

, Volume 12, Issue 10, pp 646–656 | Cite as

Hyperkalemia in the elderly

Drugs exacerbate impaired potassium homeostasis
  • Mark A. Perazella
  • Rex L. Mahnensmith
Clinical Review

Abstract

Objective

To review the pathophysiology underlying the predisposition to hyperkalemia in the elderly; the medications that disrupt potassium balance and promote the development of hyperkalemia in the elderly; the prevention of hyperkalemia in elderly patients treated with potassium-altering medications; and the appropriate management of hyperkalemia when it develops.

Methods and main results

A MEDLINE search of the literature (1966–1996) using the terms hyperkalemia, drugs, elderly, and treatment was conducted and pertinent review articles, textbooks, and personal files were consulted. Elderly subjects appear to be predisposed to the development of hyperkalemia on the basis of both innate disturbances in potassium homeostasis and comorbid disease processes that impair potassium handling. Hyperkalemia in the elderly is most often precipitated by medications that impair cellular uptake or renal disposal of potassium. This electrolyte disorder is best prevented by recognition of at-risk physiology in the aged, avoidance of therapy with certain high-risk medications, and monitoring of plasma potassium concentration and renal function at intervals appropriate for the medication prescribed. Management of hyperkalemia entails identification of the clinical manifestations of severe hyperkalemia, stabilization of cardiac tissue, promotion of cellular potassium uptake, and ultimately removal of potassium from the body.

Conclusions

Geriatric patients should be considered at risk of developing hyperkalemia, especially when they are prescribed certain medications. Potassium levels should be monitored at appropriate intervals when these patients are treated with potassium-altering medications. Appropriate management of hyperkalemia in the elderly can avoid life-threatening neuromuscular and cardiac complications.

Key words

hyperkalemia elderly drugs hypoaldosteronism treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Michelis MH. Hyperkalemia in the elderly. Am J Kidney Dis. 1990;16:296–9.PubMedGoogle Scholar
  2. 2.
    Kleinfeld M, Corcoran AJ. Hyperkalemia in the elderly. Compr Ther. 1990;16:49–53.PubMedGoogle Scholar
  3. 3.
    Choi MJ, Fernandez PC, Coupaye-Gerard B, et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328:703–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Greenberg S, Reiser IW, Chou SY, et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med. 1993;119:291–5.PubMedGoogle Scholar
  5. 5.
    Velazquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296–301.PubMedGoogle Scholar
  6. 6.
    Alappan R, Perazella MA, Buller GK. Trimethoprim-sulfamethoxazole in standard dose causes hyperkalemia. J Am Soc Nephrol. 1995;6:437. Abstract.Google Scholar
  7. 7.
    Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124:316–20.PubMedGoogle Scholar
  8. 8.
    Canady DH, Johnson JR. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med. 1994;120:437–8. Letter.Google Scholar
  9. 9.
    Medina I, Mills J, Leoung G, et al. Oral therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:776–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Marinella MA. Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole. Am J Med Sci. 1995;310:115–7.PubMedGoogle Scholar
  11. 11.
    Smith GW, Cohen SB. Hyperkalemla and non-oliguric renal failure associated with trimethoprim. BMJ. 1994;308:454. Letter.PubMedGoogle Scholar
  12. 12.
    Pennypacker LC, Mintzer J, Pitner J. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med. 1994;120:437. Letter.PubMedGoogle Scholar
  13. 13.
    Modest GA, Price B, Mascoli N. Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole. Ann Intern Med. 1994;120:437. Letter.PubMedGoogle Scholar
  14. 14.
    Tauchi H, Tsuboi K, Okutomi J. Age changes in the human kidney of the different races. Gerontologia. 1971;17:87–97.PubMedCrossRefGoogle Scholar
  15. 15.
    McDonald RK, Solomon DH, Shock NW. Aging as a factor in the renal hemodynamic changes induced by standardized pyrogen. J Clin Invest. 1951;30:457–62.PubMedGoogle Scholar
  16. 16.
    Hollenberg NK, Adams DF, Solomon HS. Senescence and the renal vasculature in normal man. Circ Res. 1974;34:309–16.PubMedGoogle Scholar
  17. 17.
    Baylis C, Fredericks M, Wilson C, et al. Renal vasodilatory response to intravenous glycine in the aging rat kidney. Am J Kidney Dis. 1990;15:244–51.PubMedGoogle Scholar
  18. 18.
    Rowe JW, Andres R, Tobin JD, et al. Age-adjusted standards for creatinine clearance. Ann Intern Med. 1976;84:567–9.PubMedGoogle Scholar
  19. 19.
    Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278–85.PubMedGoogle Scholar
  20. 20.
    Luft FC, Fineberg NS, Miller JŽ, et al. The effects of age, race, and heredity on glomerular filtration rate following volume expansion and contraction in normal man. Am J Med Sci. 1980;279:15–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Epstein M, Hollenberg NK. Age as a determinant of renal sodium conservation in normal man. J Lab Clin Med. 1976;87:411–7.PubMedGoogle Scholar
  22. 22.
    Adler S, Lindeman RD, Yiengst MJ, et al. Effect of acute acid loading in primary acid excretion by the aging human kidney. J Lab Clin Med. 1968;72:278–89.PubMedGoogle Scholar
  23. 23.
    Hostetter TH, Rennke HG, Brenner B. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982;72:375–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Brenner B, Meyer T, Hostetter TH. Dietary protein intake and the progressive nature of renal disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med. 1986;80:435–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Takazakura E, Sawabu N, Handa A, et al. Intrarenal vascular changes with age and disease. Kidney Int. 1972;2:224–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Rowe J, Andres R, Tobin J, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155–63.PubMedGoogle Scholar
  28. 28.
    DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 1980;17:118–34.PubMedCrossRefGoogle Scholar
  29. 29.
    Tan SY, Burton M. Hyporeninemic hypoaldosteronism. Arch Intern Med. 1981;141:30–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Mulkerrin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol. 1995; 6:1459–62.PubMedGoogle Scholar
  31. 31.
    Good DW, Wright FS. Luminal influences on potassium secretion: sodium concentration and fluid flow rate. Am J Physiol. 1979;236:F192–205.PubMedGoogle Scholar
  32. 32.
    Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal tubular acidosis associated with obstructive uropathy. N Engl J Med. 1981;304:373–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Phillips PA, Rolls BJ, Ledingham JGG, et al. Reduced thirst after water deprivation in healthy elderly men. N Engl J Med. 1984; 311:753–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Lawson DH. Adverse reactions to potassium chloride. QJM. 1974;43:433–40.PubMedGoogle Scholar
  35. 35.
    Lawson DH, O’Connor PC, Jick H. Drug attributed alterations in potassium handling in congestive heart failure. Eur J Clin Pharmacol. 1982;23:21–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Paice B, Gray JMB, McBride D, et al. Hyperkalemia in patients in hospital, BMJ. 1983;286:1189–92.PubMedGoogle Scholar
  37. 37.
    Shapiro S, Slone D, Lewis GP, et al. Fatal drug reactions among medical inpatients. JAMA. 1971;216:467–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Shemer J, Ezra D, Modan M, et al. Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci. 1983;19:659–61.PubMedGoogle Scholar
  39. 39.
    McCaughan D. Hazards of non-prescription potassium supplements. Lancet. 1984;1:513–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Ponce SP, Jennings AE, Madias NE, et al. Drug-induced hyperkalemia. Medicine. 1985;64:357–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Cannon-Babb M, Schwartz AB. Drug-induced hyperkalemia. Hosp Pract. 1986;21:99–127.Google Scholar
  42. 42.
    Laragh JH. Amiloride, a potassium-conserving agent new to the USA: mechanisms and clinical relevance. Curr Ther Res. 1982; 32:173–88.Google Scholar
  43. 43.
    Ramsay LE, Hettiarachchi J, Fraser R, et al. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol. 1980;4:533–43.Google Scholar
  44. 44.
    Udezue FU, Harrold BP. Hyperkalaemic paralysis due to spironolactone. Postgrad Med J. 1980;56:254–5.PubMedGoogle Scholar
  45. 45.
    Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. JAMA. 1973;225:40–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Whiting FM, McLaran CJ, Bochner F. Severe hyperkalaemia with Moduretic. Med J Aust. 1979;1:409. Letter.PubMedGoogle Scholar
  47. 47.
    McDonald CJ. Dyazide and hyperkalemia. Ann Intern Med. 1976; 84:612–3.Google Scholar
  48. 48.
    Feinfeld DA, Carvounis CP. Fatal hyperkalemia and hyperchloremic acidosis. Association, with spironolactone in the absence of renal impairment. JAMA. 1978;240:1516. Letter.PubMedCrossRefGoogle Scholar
  49. 49.
    Jaffey L, Martin A. Malignant hyperkalemia after amiloride/hydrochlorothiazide treatment. Lancet. 1981;1:1272. Letter.PubMedCrossRefGoogle Scholar
  50. 50.
    McNay JL, Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretics, amiloride (MK-870). Metabolism. 1970;19:58–70.PubMedCrossRefGoogle Scholar
  51. 51.
    Mor R, Pitlik S, Rosenfeld JB. Indomethacin and moduretic-induced hyperkalemia. Isr J Med Sci. 1983;19:535–7.PubMedGoogle Scholar
  52. 52.
    Walker BR, Capuzzi DM, Alexander F, et al. Hyperkalemia after triamterene in diabetic patients. Clin Pharmacol Ther. 1972;13: 643–51.PubMedGoogle Scholar
  53. 53.
    Wan HH, Lye MDW. Moduretic-induced metabolic acidosis and hyperkalemia. Postgraduate Med J. 1980;56:348. Letter.Google Scholar
  54. 54.
    Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44:643–53.PubMedCrossRefGoogle Scholar
  55. 55.
    Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1984;310:563–72.PubMedCrossRefGoogle Scholar
  56. 56.
    Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 1984;63:165–81.PubMedCrossRefGoogle Scholar
  57. 57.
    Goldszer RC, Coodley EL, Rosner MJ, et al. Hyperkalemia associated with indomethacin. Arch Intern Med. 1981;141:802–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Tan SY, Shapiro R, Franco R, et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med. 1979; 90:783–5.PubMedGoogle Scholar
  59. 59.
    Miller KP, Lazar EJ, Fotino S. Severe hyperkalemia during piroxicam therapy. Arch Intern Med. 1984;144:2414–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Meier DE, Myers, M, Swenson R, et al. Indomethacin-associated hyperkalemia in the elderly. J Am Geriatr Soc. 1983;31:371–3.PubMedGoogle Scholar
  61. 61.
    Beroniade V, Corneille L, Haraoui B. Indomethacin-induced inhibition of prostaglandin with hyperkalemia. Ann, Intern Med. 1979;91:499–500.Google Scholar
  62. 62.
    Corwin HL, Bonventre JV. Renal insufficiency associated with nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 1984;4: 147–52.PubMedGoogle Scholar
  63. 63.
    Findling JW, Beckstrom D, Rawsthorne L, et al. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA. 1980;244:1127–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Frais MA, Burgess A, Mitchell LB, et al. Piroxicam-induced renal failure and hyperkalemia. Ann Intern Med. 1983;99:129–30.PubMedGoogle Scholar
  65. 65.
    Galler M, Folkert VW, Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA. 1982;246:154–5.CrossRefGoogle Scholar
  66. 66.
    Nicholls MG, Espiner EA. Indomethacin-induced azotemia and hyperkalemia. N Ž Med J. 1981;94:377–9.PubMedGoogle Scholar
  67. 67.
    Textor SC, Bravo EL, Fouad FM, et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med. 1982;73:719–25.PubMedCrossRefGoogle Scholar
  68. 68.
    Atlas SA, Case DB, Sealey JE, et al. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension. 1979;1:274–80.PubMedGoogle Scholar
  69. 69.
    Bethune DW, McKay R. Paradoxical changes in serum potassium during cardiopulmonary bypass in association with non-cardioselective beta-blockage. Lancet. 1978;2:380–1.PubMedCrossRefGoogle Scholar
  70. 70.
    Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand. 1983;672: 121–32.Google Scholar
  71. 71.
    DeFronzo RA, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int. 1981;20:83–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Rosa RM, Silva P, Young JB, et al. Adrenergic modulation of extrarenal potassium disposal. N Engl J Med. 1980;302:431–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Traub YM, Rabinov M, Rosenfeld JB, et al. Elevation of serum potassium during beta-blockade: absence of relationship to the renin-aldosterone system. Clin Pharmacol Ther. 1980;28:765–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Bia MJ, DeFronzo RA. Extrarenal potassium homeostasis. Am J Physiol. 1981;240:F257–68.PubMedGoogle Scholar
  75. 75.
    Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575–86.PubMedCrossRefGoogle Scholar
  76. 76.
    Lown B, Black H, Moore FD, et al. Digitalis, electrolytes and the surgical patient. Am J Cardiol. 1960;6:309–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Smith TW, Butler VP, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab fragments. N Engl J Med. 1982;307:1357–62.PubMedCrossRefGoogle Scholar
  78. 78.
    Smith TW, Willerson JT. Suicidal and accidental digoxin ingestion. Report of five cases with serum digoxin level correlations. Circulation. 1971;44:29–36.PubMedGoogle Scholar
  79. 79.
    Reza MJ, Kovick RB, Shine KI, et al. Massive intravenous digoxin overdosage. N Engl J Med. 1974;291:777–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Kaufman AM, Hellman G, Abramson RG. Renal salt wasting and metabolic acidosis with trimethoprim-sulfamethoxazole therapy. Mt Sinal J Med. 1983;50:238–9.Google Scholar
  81. 81.
    Acker CG, Johnson JP, Palevsky M, Greenburg A. Hyperkalemia in the hospital. J Am Soc Nephrol. 1996;7:1346. Abstract.Google Scholar
  82. 82.
    Emanuel M, Metcalf RG. Quadriplegia in hyperkalemia. J Maine Med Assoc. 1966;157:134–7.Google Scholar
  83. 83.
    Pollen RH, Williams RH. Hyperkalemic neuromyopathy in Addison’s disease. N Engl J Med. 1960;263:273–8.PubMedCrossRefGoogle Scholar
  84. 84.
    DeFronzo RA, Smith JD. Disorders of potassium metabolism-hyperkalemia. In: Arieff AI, DeFronzo RA, editors. Fluid, Electrolyte and Acid-Base Disorders. New York, NY: Churchill-Livingstone: 1995;319.Google Scholar
  85. 85.
    DeFronzo RA, Thier SO. Fluid and electrolyte disturbances: hypo- and hyperkalemia. In: Martinez-Maldonado, M, ed. Handbook of Renal Theurapeutics. Plenum: New York, NY: 1983:25.Google Scholar
  86. 86.
    Giebisch GH, Thier SO. Potassium: physiological and clinical importance. In: Siegel L, ed. Directions in Cardiovascular Medicine. Somerville, NJ: Hoechst-Roussel Pharmaceuticals: 1977:48.Google Scholar
  87. 87.
    Clausen T, Flatman JA. Effects of insulin and epinephrine on Na+−K+ and glucose transport in soleus muscle. Am J Physiol. 1987;252:E492–9.PubMedGoogle Scholar
  88. 88.
    Moore RD. Stimulation of Na:H exchange by insulin. Biophys J. 1981;33:203–10.PubMedGoogle Scholar
  89. 89.
    Burton SD, Mondon CE, Ishida J. Dissociation of potassium and glucose efflux in isolated perfused rat liver. Am J Physiol. 1967: 212:261–6.PubMedGoogle Scholar
  90. 90.
    Clausen T, Hansen O. Active Na−K transport and the rate of oubain binding: the effect of insulin and other stimuli on skeletal muscle and adipocytes. J Physiol (Lond). 1977;270:415–30.Google Scholar
  91. 91.
    Gourley DRH. Effect of insulin on potassium exchange in normal and oubain-treated skeletal muscle. J Pharmacol Exp Ther. 1965; 148:339–47.PubMedGoogle Scholar
  92. 92.
    Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989; 110:426–9.PubMedGoogle Scholar
  93. 93.
    Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38:869–72.PubMedCrossRefGoogle Scholar
  94. 94.
    Burgess CD, Flatt A, Siebers R, et al. A comparison of the extent and duration of hypokalemia following three nebulized beta 2-adrenoceptor agonists. Eur J Clin Pharmacol. 1989;36:415–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Spital A. Bicarbonate in the treatment of severe hyperkalemia. Am J Med. 1989;86:511–2.PubMedCrossRefGoogle Scholar
  96. 96.
    Blumberg A, Weidmann P, Shaw S, et al. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85:507–12.PubMedCrossRefGoogle Scholar
  97. 97.
    Scheer L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation exchange resin. N Engl J Med. 1961;264:115–9.CrossRefGoogle Scholar
  98. 98.
    Ward RA, Wathen RL, Williams TE, et al. Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes. Kidney Int. 1987;32:129–35.PubMedCrossRefGoogle Scholar
  99. 99.
    Feig PU, Shook A, Sterns RH. Effect of potassium removal during hemodialysis on the plasma potassium concentration. Nephron. 1981;27:25–30.PubMedGoogle Scholar
  100. 100.
    Boen ST. Kinetics of periotoneal dialysis: a comparison with the artificial kidney. Medicine (Baltimore). 1961;40:243–87.Google Scholar
  101. 101.
    Redaelli B, Locatelli F, Limido D, et al. Effect of a new model of hemodialysis potassium removal on the control of ventricular arrhythmias. Kidney Int. 1996;50:609–17.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 1997

Authors and Affiliations

  • Mark A. Perazella
    • 1
  • Rex L. Mahnensmith
    • 1
  1. 1.Section of Nephrology, Dept. Of Medicine, LMP 2071Yale Univ School of MedicineNew Haven

Personalised recommendations